Liposome composition for delivery of nucleic acid
A liposome composition for delivery of a nucleic acid in vivo or ex vivo is described. The liposomes in the composition are comprised of (i) a lipid that is neutral in charge at physiologic pH and positively charged at pH values less than physiologic pH and (ii) a lipid joined to a hydrophilic polymer by a dithiobenzyl linkage. The liposomes are associated with a nucleic acid for delivery to a cell.
1. A composition for administration of a nucleic acid, comprising:
(a) liposomes comprised of
(i) a lipid having the formula
where each of R 1 and R 2 is an alkyl or alkenyl chain having between 8-24 carbon atoms, and each of R 1 or R 2 are independently selected;
n=0-20;
L is selected from the group consisting of (1) —X—(C═O)—Y—[[CH 2 —]], (2) —X—(C═O)—, and (3) —X—[[CH 2 —]], where X and Y are independently selected from oxygen, NH and a direct bond;
Z is a weakly basic moiety that has a pk of less than 7.4 and greater than about 4.0; and
(ii) a compound having the general structure:
wherein R 3 is a hydrophilic polymer comprising a linkage for attachment to the dithiobenzyl moiety; R 4 is selected from the group consisting of H, alkyl and aryl; R 5 is selected from the group consisting of O(C═O)R 7 , S(C═O)R 7 , and O(C═S)R 7 ; R 7 comprises an amine-containing lipid; and R 6 is selected from the group consisting of H, alkyl and aryl; and where orientation of CH 2 —R 5 is selected from the ortho position and the para position; and
(b) a nucleic acid associated with said liposomes.
2. The composition of claim 1 , wherein X is NH and Y is oxygen.
3. The composition of claim 1 , wherein L is a carbamate linkage, an ester linkage, or a carbonate linkage.
4. The composition of claim 1 , wherein L is NH—(C═O)—O—[[CH 2 ]].
5. The composition of claim 1 , wherein Z is an imidazole.
6. The composition of claim 1 , comprising between 1-80 mole percent of the lipid.
7. The composition of claim 1 , wherein Z is a moiety having a pK value between 5.0-6.5.
8. The composition of claim 1 , wherein each of R 1 and R 2 is an unbranched alkyl or alkenyl chain having between 8-24 carbon atoms.
9. The composition of claim 8 , wherein each of R 1 and R 2 is C 17 H 35 .
10. The composition of claim 1 , wherein n is between 1-10.
11. The composition of claim 1 , wherein R 6 is H and R 4 is selected from the group consisting of CH 3 , C 2 H 5 and C 3 H 8 .
12. The composition of claim 1 , wherein the amine-containing lipid comprises either a single hydrocarbon tail or a double hydrocarbon tail.
13. The composition of claim 1 , wherein the amine-containing lipid is a phospholipid having a double hydrocarbon tail.
14. The composition of claim 1 , wherein R 4 and R 6 are alkyls.
15. The composition of claim 1 , wherein R 3 is selected from the group consisting of polyvinylpyrrolidone, polyvinylmethylether, polymethyloxazoline, polyethyloxazoline, polyhydroxypropyloxazoline, polyhydroxypropyl-methacrylamide, polymethacrylamide, polydimethyl-acrylamide, polyhydroxypropylmethacrylate, polyhydroxyethylacrylate, hydroxymethylcellulose, hydroxyethylcellulose, polyethyleneglycol, polyaspartamide, copolymers thereof, and polyethyleneoxide-polypropylene oxide.
16. The composition of claim 1 , wherein R 3 is polyethyleneglycol.
17. The composition of claim 16 , wherein R 6 is H and R 4 is CH 3 or C 2 H 5 .
18. The composition of claim 1 , wherein said liposomes include between 5-20 mole percent of the compound.
19. The composition of claim 1 , further including a therapeutic compound entrapped in the liposomes.
20. The composition of claim 1 , wherein said nucleic acid is entrapped in at least a portion of said liposomes.
21. The composition of claim 20 , wherein the nucleic acid is selected from DNA, RNA, fragments thereof and oligonucleotides.
22. The composition of claim 1 , further including a ligand for targeting the liposomes to a target site, said ligand covalently attached to a distal end of the hydrophilic polymer R 3 on said compound.
23. The composition of claim 22 , wherein the ligand has binding affinity for endothelial tumor cells for internalization by such cells.
24. The composition of claim 22 , wherein the ligand is selected from the group consisting of E-selectin, Her-2 and FGF.
25. The composition of claim 22 , wherein said ligand is selected from the group consisting of c-erbB-2 protein product of the HER2/neu oncogene, epidermal growth factor (EGF) receptor, basic fibroblast growth receptor (basic FGF) receptor, vascular endothelial growth factor receptor, E-selectin receptor, L-selectin receptor, P-selectin receptor, folate receptor, CD4 receptor, CD19 receptor, αβ integrin receptors, and chemokine receptors.
26. The composition of claim 1 , wherein said liposomes further comprise a cationic lipid.